Abstract. Immune escape mechanisms in non-small cell lung cancer (NSCLC) can disrupt every step of the anti-cancer immune response. In recent years, an increased understanding of the specific mechanisms fueling immune escape has allowed for the development of numerous immunotherapeutic treatments that have been introduced into the clinical practice. The advent of immunotherapy has dramatically changed the current treatment landscape of advanced or metastatic NSCLC because of its durable efficacy and manageable toxicity. In this review, we will first present a brief overview of recent evidence on immune escape mechanisms in NSCLC. We will then discuss the current promising immunotherapeutic strategies in advanced or metastatic NSCLC tumors
The identification of tumor “oncogenic drivers” and the subsequent development of targeted therapy ...
Immunotherapy has revolutionised anti-cancer treatment in solid organ malignancies. Specifically, th...
The identification of tumor “oncogenic drivers” and the subsequent development of targeted therapy ...
Lung cancer has been historically considered a poorly immunogenic disease because of the few evidenc...
Lung cancer has been historically considered a poorly immunogenic disease because of the few evidenc...
In the last few years, the introduction of novel immunotherapeutic agents has represented a treatmen...
Immunotherapy has significantly altered the treatment landscape for many cancers, including non-smal...
Immunotherapy has significantly altered the treatment landscape for many cancers, including non-smal...
In the past several years, immunotherapy has emerged as a viable treatment option for patients with ...
In recent years, the five-year survival rate of patients with advanced stage non-small cell lung can...
Immune checkpoint inhibitors have shown efficacy in the treatment of non-small cell lung cancer (NSC...
Immune checkpoint inhibitors have shown efficacy in the treatment of non-small cell lung cancer (NSC...
Tumor immune escape has emerged as the most significant barrier to cancer therapy. A thorough unders...
Abstract Recent breakthroughs in targeted therapy and immunotherapy have revolutionized the treatmen...
Immunotherapy using immune checkpoint modulators has revolutionized the oncology field, emerging as ...
The identification of tumor “oncogenic drivers” and the subsequent development of targeted therapy ...
Immunotherapy has revolutionised anti-cancer treatment in solid organ malignancies. Specifically, th...
The identification of tumor “oncogenic drivers” and the subsequent development of targeted therapy ...
Lung cancer has been historically considered a poorly immunogenic disease because of the few evidenc...
Lung cancer has been historically considered a poorly immunogenic disease because of the few evidenc...
In the last few years, the introduction of novel immunotherapeutic agents has represented a treatmen...
Immunotherapy has significantly altered the treatment landscape for many cancers, including non-smal...
Immunotherapy has significantly altered the treatment landscape for many cancers, including non-smal...
In the past several years, immunotherapy has emerged as a viable treatment option for patients with ...
In recent years, the five-year survival rate of patients with advanced stage non-small cell lung can...
Immune checkpoint inhibitors have shown efficacy in the treatment of non-small cell lung cancer (NSC...
Immune checkpoint inhibitors have shown efficacy in the treatment of non-small cell lung cancer (NSC...
Tumor immune escape has emerged as the most significant barrier to cancer therapy. A thorough unders...
Abstract Recent breakthroughs in targeted therapy and immunotherapy have revolutionized the treatmen...
Immunotherapy using immune checkpoint modulators has revolutionized the oncology field, emerging as ...
The identification of tumor “oncogenic drivers” and the subsequent development of targeted therapy ...
Immunotherapy has revolutionised anti-cancer treatment in solid organ malignancies. Specifically, th...
The identification of tumor “oncogenic drivers” and the subsequent development of targeted therapy ...